KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) Operating Income: 2009-2024

Historic Operating Income for Novavax (NVAX) over the last 16 years, with Dec 2024 value amounting to -$248.9 million.

  • Novavax's Operating Income fell 32.83% to -$178.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $307.5 million, marking a year-over-year increase of 202.01%. This contributed to the annual value of -$248.9 million for FY2024, which is 56.06% up from last year.
  • Per Novavax's latest filing, its Operating Income stood at -$248.9 million for FY2024, which was up 56.06% from -$566.5 million recorded in FY2023.
  • Novavax's 5-year Operating Income high stood at -$248.9 million for FY2024, and its period low was -$1.7 billion during FY2021.
  • Over the past 3 years, Novavax's median Operating Income value was -$566.5 million (recorded in 2023), while the average stood at -$486.7 million.
  • Per our database at Business Quant, Novavax's Operating Income plummeted by 304.73% in 2021 and then soared by 61.77% in 2022.
  • Yearly analysis of 5 years shows Novavax's Operating Income stood at -$416.7 million in 2020, then tumbled by 304.73% to -$1.7 billion in 2021, then soared by 61.77% to -$644.7 million in 2022, then climbed by 12.13% to -$566.5 million in 2023, then surged by 56.06% to -$248.9 million in 2024.